Methicillin-Susceptible Staphylococcus aureus (MSSA) Infections – Pipeline Review, H2 2016

Global Markets Direct’s, ‘Methicillin-Susceptible Staphylococcus aureus (MSSA) Infections – Pipeline Review, H2 2016’, provides an overview of the Methicillin-Susceptible Staphylococcus aureus (MSSA) Infections pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Methicillin-Susceptible Staphylococcus aureus (MSSA) Infections, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Methicillin-Susceptible Staphylococcus aureus (MSSA) Infections and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

The report provides a snapshot of the global therapeutic landscape of Methicillin-Susceptible Staphylococcus aureus (MSSA) Infections

The report reviews pipeline therapeutics for Methicillin-Susceptible Staphylococcus aureus (MSSA) Infections by companies and universities/research institutes based on information derived from company and industry-specific sources

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved Methicillin-Susceptible Staphylococcus aureus (MSSA) Infections therapeutics and enlists all their major and minor projects

The report assesses Methicillin-Susceptible Staphylococcus aureus (MSSA) Infections therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news related to pipeline therapeutics for Methicillin-Susceptible Staphylococcus aureus (MSSA) Infections

Reasons to buy

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand important and diverse types of therapeutics under development for Methicillin-Susceptible Staphylococcus aureus (MSSA) Infections

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Methicillin-Susceptible Staphylococcus aureus (MSSA) Infections pipeline depth and focus of Indication therapeutics

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Companies mentioned

Arsanis, Inc.

ContraFect Corporation

Debiopharm International SA

Sealife PHARMA GMBH

Sumitomo Dainippon Pharma Co Ltd

Table of Contents

Table of Contents

Table of Contents 2

List of Tables 4

List of Figures 4

Introduction 5

Global Markets Direct Report Coverage 5

Methicillin-Susceptible Staphylococcus aureus (MSSA) Infections Overview 6

Therapeutics Development 7

Pipeline Products for Methicillin-Susceptible Staphylococcus aureus (MSSA) Infections - Overview 7

Pipeline Products for Methicillin-Susceptible Staphylococcus aureus (MSSA) Infections - Comparative Analysis 8

Methicillin-Susceptible Staphylococcus aureus (MSSA) Infections - Therapeutics under Development by Companies 9

Methicillin-Susceptible Staphylococcus aureus (MSSA) Infections - Therapeutics under Investigation by Universities/Institutes 10

Methicillin-Susceptible Staphylococcus aureus (MSSA) Infections - Pipeline Products Glance 11

Clinical Stage Products 11

Early Stage Products 12

Methicillin-Susceptible Staphylococcus aureus (MSSA) Infections - Products under Development by Companies 13

Methicillin-Susceptible Staphylococcus aureus (MSSA) Infections - Products under Investigation by Universities/Institutes 14

Methicillin-Susceptible Staphylococcus aureus (MSSA) Infections - Companies Involved in Therapeutics Development 15

Arsanis, Inc. 15

ContraFect Corporation 16

Debiopharm International SA 17

Sealife PHARMA GMBH 18

Sumitomo Dainippon Pharma Co Ltd 19

Methicillin-Susceptible Staphylococcus aureus (MSSA) Infections - Therapeutics Assessment 20

Assessment by Monotherapy Products 20

Assessment by Target 21

Assessment by Mechanism of Action 23

Assessment by Route of Administration 25

Assessment by Molecule Type 27

Drug Profiles 29

ASN-100 - Drug Profile 29

Product Description 29

Mechanism Of Action 29

R&D Progress 29

CF-301 - Drug Profile 31

Product Description 31

Mechanism Of Action 31

R&D Progress 31

Debio-1450 - Drug Profile 34

Product Description 34

Mechanism Of Action 34

R&D Progress 34

NAI-108 - Drug Profile 36

Product Description 36

Mechanism Of Action 36

R&D Progress 36

SLP-0904 - Drug Profile 37

Product Description 37

Mechanism Of Action 37

R&D Progress 37

SLP-0905 - Drug Profile 38

Product Description 38

Mechanism Of Action 38

R&D Progress 38

SM-295291 - Drug Profile 39

Product Description 39

Mechanism Of Action 39

R&D Progress 39

SM-369926 - Drug Profile 40

Product Description 40

Mechanism Of Action 40

R&D Progress 40

Small Molecules for Bacterial Infections - Drug Profile 41

Product Description 41

Mechanism Of Action 41

R&D Progress 41

Synthetic Peptide for Oncology and Infectious Disease - Drug Profile 42

Product Description 42

Mechanism Of Action 42

R&D Progress 42

targocil - Drug Profile 43

Product Description 43

Mechanism Of Action 43

R&D Progress 43

Methicillin-Susceptible Staphylococcus aureus (MSSA) Infections - Dormant Projects 44

Methicillin-Susceptible Staphylococcus aureus (MSSA) Infections - Discontinued Products 45

Methicillin-Susceptible Staphylococcus aureus (MSSA) Infections - Product Development Milestones 46

Featured News & Press Releases 46

Dec 02, 2014: ContraFect Submits Complete Response to IND Clinical Hold for CF-301 46

Appendix 47

Methodology 47

Coverage 47

Secondary Research 47

Primary Research 47

Expert Panel Validation 47

Contact Us 47

Disclaimer 48

List of Tables

List of Tables

Number of Products under Development for Methicillin-Susceptible Staphylococcus aureus (MSSA) Infections, H2 2016 7

Number of Products under Development for Methicillin-Susceptible Staphylococcus aureus (MSSA) Infections – Comparative Analysis, H2 2016 8

Number of Products under Development by Companies, H2 2016 9

Number of Products under Investigation by Universities/Institutes, H2 2016 10

Comparative Analysis by Clinical Stage Development, H2 2016 11

Comparative Analysis by Early Stage Development, H2 2016 12

Products under Development by Companies, H2 2016 13

Products under Investigation by Universities/Institutes, H2 2016 14

Methicillin-Susceptible Staphylococcus aureus (MSSA) Infections – Pipeline by Arsanis, Inc., H2 2016 15

Methicillin-Susceptible Staphylococcus aureus (MSSA) Infections – Pipeline by ContraFect Corporation, H2 2016 16

Methicillin-Susceptible Staphylococcus aureus (MSSA) Infections – Pipeline by Debiopharm International SA , H2 2016 17

Methicillin-Susceptible Staphylococcus aureus (MSSA) Infections – Pipeline by Sealife PHARMA GMBH, H2 2016 18

Methicillin-Susceptible Staphylococcus aureus (MSSA) Infections – Pipeline by Sumitomo Dainippon Pharma Co Ltd, H2 2016 19

Assessment by Monotherapy Products, H2 2016 20

Number of Products by Stage and Target, H2 2016 22

Number of Products by Stage and Mechanism of Action, H2 2016 24

Number of Products by Stage and Route of Administration, H2 2016 26

Number of Products by Stage and Molecule Type, H2 2016 28

Methicillin-Susceptible Staphylococcus aureus (MSSA) Infections – Dormant Projects, H2 2016 44

Methicillin-Susceptible Staphylococcus aureus (MSSA) Infections – Discontinued Products, H2 2016 45

List of Figures

List of Figures

Number of Products under Development for Methicillin-Susceptible Staphylococcus aureus (MSSA) Infections, H2 2016 7

Number of Products under Development for Methicillin-Susceptible Staphylococcus aureus (MSSA) Infections – Comparative Analysis, H2 2016 8

Number of Products under Development by Companies, H2 2016 9

Number of Products under Investigation by Universities/Institutes, H2 2016 10

Comparative Analysis by Clinical Stage Development, H2 2016 11

Comparative Analysis by Early Stage Products, H2 2016 12

Assessment by Monotherapy Products, H2 2016 20

Number of Products by Targets, H2 2016 21

Number of Products by Stage and Targets, H2 2016 21

Number of Products by Mechanism of Actions, H2 2016 23

Number of Products by Stage and Mechanism of Actions, H2 2016 23

Number of Products by Routes of Administration, H2 2016 25

Number of Products by Stage and Routes of Administration, H2 2016 25

Number of Products by Molecule Types, H2 2016 27

Number of Products by Stage and Top 10 Molecule Types, H2 2016 27

    Pricing

Discounts available for multiple purchases.

reportstore@globalmarketsdirect.com
+44 20 7947 2745

Saved reports